T Cell News and Research

Latest T Cell News and Research

Ruthenium and Osmium compounds show high levels of activity against ovarian cancer

Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.

19 Oct 2009

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection.

19 Oct 2009

Research study provides supportive evidence for using ATR inhibitors in cancer therapy

A study published in the October issue of Nature Genetics demonstrates that loss of the tumor-suppressor protein p53, coupled with elimination of the DNA-maintenance protein ATR, severely disrupts tissue maintenance in mice.

19 Oct 2009

Gates Foundation to announce grants to promote agriculture at world food prize symposium

During a "keynote speech" Thursday at the World Food Prize Symposium in Des Moines, Iowa, Bill Gates, cofounder of the Bill & Melinda Gates Foundation, is expected to announce $120 million in grants "to promote dynamic, home-grown, sustainable agriculture in Africa and India,"

19 Oct 2009

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming.

19 Oct 2009

Rituxan drug effective for treating ANCA-associated vasculitis

Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy.

19 Oct 2009

Findings provide new insight on skin pigmentation

The skin's pigment cells can be formed from completely different cells than has hitherto been thought, a new study from the Swedish medical university Karolinska Institutet shows. The results, which are published in the journal Cell, also mean the discovery of a new kind of stem cell.

19 Oct 2009

Findings may yield new treatments for COPD

A genetic mutation found in four children born with multiple abnormalities may provide insight into potential treatments for newborn lung distress and chronic obstructive pulmonary disease (COPD).

19 Oct 2009

Asthma is the most common underlying condition associated with H1N1 Swine Flu: CDC Report

Cannabis Science Inc., an emerging pharmaceutical cannabis company, notes a report by epidemiologists at the Centers for Disease Control and Prevention (CDC) saying that, among people hospitalized with severe cases of the pandemic strain of H1N1 Swine Flu, asthma is by far the most common underlying condition associated with he disease.

19 Oct 2009

APP balance critical for normal neuronal development

New data about amyloid precursor protein, or APP, a protein implicated in development of Alzheimer's disease, suggests it also may have a positive role -- directly affecting learning and memory during brain development. So is APP good or bad? Researchers at Georgetown University Medical Center say both, and that a balance of APP is critical.

19 Oct 2009

Enzo Biochem to release a new catalog dealing with epigenetics and chromatin modification

Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with “Epigenetics & Chromatin Modification” at the Society for Neuroscience’s, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.

15 Oct 2009

Overview of innovative technology for treating ischemic and autoimmune disorders

Pluristem Therapeutics Inc. today announced that it will present at the New England-Israel Life Sciences Summit at the Brandeis International Business School in Waltham, Mass. Zami Aberman, chairman and CEO of Pluristem will present an update on the company and an overview of its technology at 9:40 EDT, Oct 27, 2009.

15 Oct 2009

Merck KGaA and Dyesol sign joint development agreement

Merck KGaA and Dyesol Limited have signed an agreement to collaborate in the development of electrolytes for use in Dye Solar Cells (DSC).

15 Oct 2009

Prometheus Laboratories introduces three new cancer diagnostic products

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

15 Oct 2009

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Baxter International Inc. today reported solid financial results for the third quarter of 2009, and provided its fourth quarter and updated full-year 2009 financial outlook.

From Baxter International Inc. 15 Oct 2009

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

Sangretech Biomedical LLC, a developer of dendritic cell therapies for cancer and infectious diseases, today announced it has executed an amended and restated license agreement with Bostwick Laboratories, Inc. providing Bostwick Scientific, the research division of Bostwick Laboratories, with exclusive rights to Sangretech’s dendritic cell technology in certain territories.

15 Oct 2009

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Protalix BioTherapeutics, Inc., announced today positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa, previously referred to as prGCD) in treatment naive patients diagnosed with Gaucher disease.

15 Oct 2009

Cord Blood America addresses shareholder questions regarding its new laboratory in Las Vegas

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, today addressed shareholder questions about its new laboratory in Las Vegas in an interview of Matthew Schissler, founder and CEO, by analyst Francis Gaskins.

15 Oct 2009

Human brains have amazing ability to be energy efficient, say researchers

Our brains, it turns out, are eco-friendly. A study published in Science and reviewed by F1000 Biology members Venkatesh Murthy and Jakob Sorensen reveals that our brains have the amazing ability to be energy efficient.

15 Oct 2009

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

HTDS - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch cancer project working on molecular origins of lung cancer: prospects for personalized prevention and therapy. On October 8 2009, the company posted a filing on Pink Sheets titled MindUp Cancer Project.

15 Oct 2009

T Cell News and Research

Latest T Cell News and Research

Ruthenium and Osmium compounds show high levels of activity against ovarian cancer

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Research study provides supportive evidence for using ATR inhibitors in cancer therapy

Gates Foundation to announce grants to promote agriculture at world food prize symposium

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Rituxan drug effective for treating ANCA-associated vasculitis

Findings provide new insight on skin pigmentation

Findings may yield new treatments for COPD

Asthma is the most common underlying condition associated with H1N1 Swine Flu: CDC Report

APP balance critical for normal neuronal development

Enzo Biochem to release a new catalog dealing with epigenetics and chromatin modification

Overview of innovative technology for treating ischemic and autoimmune disorders

Merck KGaA and Dyesol sign joint development agreement

Prometheus Laboratories introduces three new cancer diagnostic products

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Cord Blood America addresses shareholder questions regarding its new laboratory in Las Vegas

Human brains have amazing ability to be energy efficient, say researchers

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in